Hookipa Working With Merck in Advanced Head and Neck Cancers
15 Septiembre 2021 - 7:17AM
Noticias Dow Jones
By Michael Dabaie
Hookipa Pharma Inc. said it is in a clinical collaboration and
supply agreement with Merck & Co. to evaluate HB-200 and
Keytruda for patients with advanced head and neck squamous cell
carcinoma.
Shares of Hookipa rose 5.6% to $6.57 in premarket trading.
Hookipa said the collaboration was initiated based on promising
data from the continuing HB-200 Phase 1/2 clinical trial in
advanced human papillomavirus 16-positive cancers.
With an HB-200 program data read-out anticipated by the fourth
quarter of 2021, Hookipa said it anticipates initiating a Phase 2
trial with HB-200 in combination with Keytruda in 2022. The company
said it is planning additional Phase 2 expansion cohorts to start
in the first quarter of 2022.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
September 15, 2021 08:02 ET (12:02 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Merck (NYSE:MRK)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Merck (NYSE:MRK)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024